Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus



      Our aim was to investigate the long-term efficacy and safety of canagliflozin, a sodium−glucose co-transporter 2 inhibitor, added to background sulfonylurea (SU) monotherapy for patients with type 2 diabetes mellitus.


      The CANagliflozin cardioVascularAssessment Study (CANVAS) was a double-blind, placebo-controlled cardiovascular outcomes study that randomly assigned participants to receive placebo or canagliflozin 100 or 300 mg once daily in addition to routine therapy. CANVAS included a prespecified SU substudy of patients taking background doses of SU monotherapy; data from the primary efficacy evaluation at 18 weeks have been published previously. We performed a retrospective analysis of the SU substudy at 52 weeks to measure long-term efficacy and safety of canagliflozin used with an SU. The primary objective of the long-term extension was to assess the change from baseline to 52 weeks in glycosylated hemoglobin (HbA1c).


      A total of 215 patients were included in the 52-week extension study. Patients receiving both 100-mg and 300-mg doses of canagliflozin achieved a sustained reduction in HbA1c relative to patients receiving placebo (−0.61% [95% CI, −0.941% to −0.282%] and −0.66% [95% CI, −0.993% to −0.332%], respectively), regardless of baseline HbA1c, duration of diabetes, SU dose, estimated glomerular filtration rate, or body mass index. A sustained reduction in fasting plasma glucose was also found in both 100-mg and 300-mg groups, relative to the placebo group (−2.04 mmol/L [95% CI, −2.778 to −1.299 mmol/L] and −1.88 mmol/L [95% CI, −2.623 to −1.146 mmol/L], respectively). Weight was reduced significantly at 52 weeks in both 100-mg and 300-mg groups, relative to placebo (−1.9% [95% CI, −3.2% to −0.7%] and −2.0% [95% CI, −3.2% to –0.7%], respectively). Reduction in systolic blood pressure was also reported for both dose groups relative to the placebo group, but there was no clear difference in HDL-C, LDL-C, or triglyceride levels. Canagliflozin was generally well tolerated. While documented hypoglycemia occurred in 14% of patients on placebo, the frequency of hypoglycemia with the addition of canagliflozin was similar. There was an increased frequency of genital mycotic infections in both men (5.1%) and women (10.4%) in both canagliflozin groups combined, relative to the placebo group (0%), and their frequency increased in the higher-dose group. There was a slightly higher rate of renal impairment in those treated with canagliflozin versus placebo (2.1% vs 0%).


      After 52 weeks, patients receiving canagliflozin added to background SU had sustained reductions in HbA1c and fasting plasma glucose, without increasing hypoglycemia and body weight; safety findings were generally consistent with the known safety profile of the drug. identifier: NCT01032629.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Farag Y.M.
        • Gaballa M.R.
        Diabesity: an overview of a rising epidemic.
        Nephrol Dialysis Transplant. 2011; 26 (Accessed October 2017.): 28-35
      1. National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. Accessed October 2017.

        • Sarwar N.
        • Gao P.
        • Seshasai S.R.
        • et al.
        Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.
        Lancet. 2010; 375 ( Accessed October 2017): 2215-2222
        • Liebl A.
        • Khunti K.
        • Orozco-Beltran D.
        • Yale J.F.
        Health economic evaluation of type 2 diabetes mellitus: a clinical practice focused review.
        Clin Med Insights Endocrinol Diabetes. 2015; 8 (Accessed October 2017.): 13-19
        • Inzucchi S.E.
        • Bergenstal R.M.
        • Buse J.B.
        • et al.
        Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetologia. 2012; 55: 1577-1596
        • American Diabetes Association
        Standards of medical care in diabetes--2015: summary of revisions.
        Diabetes Care. 2015; 38 (Accessed October 2017.): S4
        • Neumiller J.J.
        • White Jr., J.R.
        • Campbell R.K.
        Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
        Drugs. 2010; 70: 377-385
        • Rosenstock J.
        • Aggarwal N.
        • Polidori D.
        • et al.
        Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
        Diabetes Care. 2012; 35: 1232-1238
        • Polidori D.
        • Sha S.
        • Ghosh A.
        • et al.
        Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.
        J Clin Endocrinol Metab. 2013; 98: E867-E871
        • AstraZeneca Canada Inc
        PRFORXIGA® [product monograph].
        AstraZeneca Canada Inc, Mississauga, ON2016
        • Janssen Inc
        PrINVOKAMET® [product monograph].
        Janssen, Inc, Raritan, NJ2017
        • Boehringer Ingelheim (Canada) Ltd
        PrJARDIANCE™ [product monograph].
        Boehringer Ingelheim (Canada) Ltd, Burlington, ONJanuary 9, 2017
      2. US Food and Drug Administration. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Accessed June 1, 2017.

      3. European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. Accessed October 2017

        • Stenlof K.
        • Cefalu W.T.
        • Kim K.A.
        • et al.
        Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.
        Diabetes Obes Metab. 2013; 15: 372-382
        • Cefalu W.T.
        • Leiter L.A.
        • Yoon K.H.
        • et al.
        Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
        Lancet. 2013; 382: 941-950
        • Devineni D.
        • Morrow L.
        • Hompesch M.
        • et al.
        Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
        Diabetes Obes Metab. 2012; 14: 539-545
        • Qiu R.
        • Balis D.
        • Capuano G.
        • et al.
        Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes.
        Diabetes Ther. 2016; 7 (Accessed October 2017.): 659-678
        • Neal B.
        • Perkovic V.
        • Matthews D.R.
        • et al.
        Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.
        Diabetes Obes Metab. 2017; 19: 387-393
        • Fulcher G.
        • Matthews D.R.
        • Perkovic V.
        • et al.
        Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.
        Diabetes Ther. 2015; 6 (Accessed October 2017.): 289-302
        • Wilding J.P.
        • Charpentier G.
        • Hollander P.
        • et al.
        Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
        Int J Clin Pract. 2013; 67: 1267-1282
        • Strojek K.
        • Yoon K.H.
        • Hruba V.
        • et al.
        Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.
        Diabetes Ther. 2014; 5 (Accessed October 2017.): 267-283
        • Neal B.
        • Perkovic V.
        • Mahaffey K.W.
        • et al.
        Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
        N Engl J Med. 2017; 377 (Accessed October 2017.): 644-657